

### Factors associated with hepatocellular carcinoma ...


<https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0243473>

Dec 07, 2020 · The present study aimed to investigate the incidence of hepatocellular carcinoma (HCC) and factors related to HCC occurrence after direct-acting antiviral (DAA) treatment in the Fukushima Liver Academic Group (FLAG). We conducted a multicenter retrospective cohort study of 1068 patients without cirrhosis (NC) or with compensated liver cirrhosis (LC) who achieved a ...

### Association of Aspirin with Hepatocellular Carcinoma and ...

<https://www.nejm.org/doi/full/10.1056/NEJMoa1912035>

Background Methods Results Conclusions



More information is needed about the long-term effects of low-dose aspirin ( $\leq 160$  mg) on incident hepatocellular carcinoma, liver-related mortality, and gastrointestinal bleeding in persons with chronic hepatitis B or hepatitis C virus infection.

[See more on nejm.org](#)

Cited by: 11

Author: Tracey G Simon, Ann-Sofi Duberg, Soo A...

国内版 国际版

Long-term follow-up of cumulative incidence of hepatocellular carci



ALL IMAGES VIDEOS

79,800 Results Any time ▾

## Stratification of Hepatocellular Carcinoma Risk Following ...

<https://www.mdpi.com/2077-0383/10/2/353/htm> ▾

1 day ago · **Hepatocellular carcinoma** (HCC) incidence has dramatically decreased in **patients** infected with HCV and HBV due to the widespread use of highly effective **antiviral** agents. Nevertheless, a substantial proportion of **patients** with advanced fibrosis or cirrhosis following HCV clearance of in case of HBV control whatever the stage of fibrosis remains at risk of liver **cancer** development.

## Long-Term Risk of Hepatocellular Carcinoma in HCV Patients ...

<https://pubmed.ncbi.nlm.nih.gov/31222774>

DAA's have recently been available long enough to estimate the long-term risk. We conducted a retrospective cohort study of **hepatitis C virus** (HCV) **patients** who achieved SVR with DAAs from 129 Veterans Health Administration hospitals between January 1, 2015, and December 31, 2015, with **follow-up** through September 30, 2018.

**Cited by:** 57 **Author:** Fasiha Kanwal, Jennifer R. Kramer, Steven ...

**Publish Year:** 2020

## Long-Term Risk of Hepatocellular Carcinoma in HCV Patients ...

<https://aasldpubs.onlinelibrary.wiley.com/doi/abs/10.1002/hep.30823>

Jun 20, 2019 · Long-Term Risk of **Hepatocellular Carcinoma** in HCV **Patients** Treated With Direct Acting **Antiviral** Agents ... Among the 18,076 **patients** with SVR, 544 incident cases of HCC were diagnosed during the mean 2.9 years of **follow-up**. The **cumulative** 1, 2, and 3-year risks of HCC were 1.1%, 1.9% and 2.8%, respectively. ... Camelia Cojocariu, Anca ...

**Cited by:** 57 **Author:** Fasiha Kanwal, Jennifer R. Kramer, Steven ...

**Publish Year:** 2020

**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 60420

**Manuscript Type:** ORIGINAL ARTICLE

*Clinical Trials Study*

**Long-term follow-up of cumulative incidence of hepatocellular carcinoma in HBV patients without antiviral therapy**

Jiang XY, *et al.* HCC incidence and antiviral therapy

**Abstract**

**BACKGROUND**

China is one of the leading countries for hepatitis B virus (HBV) prevalence, but most chronic hepatitis B (CHB) patients do not receive standardized antiviral therapy. There are few relevant reports addressing the outcomes of the large number of CHB patients who do not receive antiviral therapy.

**Match Overview**

Rank	Crossref	Words	Similarity
1	Crossref	53 words	1%
	"Abstracts of the 26th Annual Conference of APASL, February 15-19, 2017, Shanghai, China", Hepatology International		
2	Crossref	30 words	<1%
	Mika Kurokawa. "Effect of interferon-α-2b plus tlbavirin therapy on incidence of hepatocellular carcinoma in patients with chronic hepatitis B", Hepatology International		
3	Crossref	14 words	<1%
	Akinori Kasahara, Norio Hayashi, Kyoshi Mochizuki, Masahide Takayanagi et al. "Risk factors for hepatocellular carcinoma in patients with chronic hepatitis B", Hepatology International		
4	Crossref	14 words	<1%
	Hideo Tanaka, Hisaki Tsukuma, Hajime Yamano, Akira Ohnima, Hiroshi Shibata. "Prospective study on the risk of hepatocellular carcinoma in patients with chronic hepatitis B", Hepatology International		
5	Crossref	14 words	<1%
	Akinobu Tawada, Tatsuo Kanda, Fumio Imazeki, Osamu Kozuka. "Prevention of hepatitis B virus-associated liver disease in patients with chronic hepatitis B", Hepatology International		
6	Crossref	13 words	<1%
	Zi-zheng Jin, Fang-fang Jin, Xin Liu, Ning Liu, Feng Wen, Jin-E Lou. "Coexistence of low levels of HBsAg and high level of anti-HBc in patients with chronic hepatitis B", Hepatology International		
7	Crossref	12 words	<1%
	"AASLD Abstracts", Hepatology, 2012.		
8	Crossref	12 words	<1%
	Tachi, Yoshihiko, Takanori Hirai, Akihiro Miyata, Kei Ohara, Tadashi Iida, Youji Ishizu, Takashi Honda, Teiji Kuzuya, Kazuo Ohno. "Effect of interferon-α-2b plus tlbavirin therapy on incidence of hepatocellular carcinoma in patients with chronic hepatitis B", Hepatology International		

### Long-Term Risk of Hepatocellular Carcinoma in HCV Patients ...

<https://pubmed.ncbi.nlm.nih.gov/31222774>

Sustained virologic response (SVR) after direct acting antiviral agents (DAAs) holds promise for reducing hepatocellular cancer (HCC). DAAs have recently been available long enough to estimate the long-term risk. We conducted a retrospective cohort study of hepatitis C virus (HCV) patients who achieved SVR.

Cited by: 57 Author: Fasiha Kanwal, Jennifer R. Kramer, Steve...

Publish Year: 2020

### Similar risk of hepatocellular carcinoma during long-term ...

<https://pubmed.ncbi.nlm.nih.gov/32553667>

Background & aims: A recent study in Asian patients with chronic hepatitis B (CHB) reported that the incidence of hepatocellular carcinoma (HCC) was lower in patients treated with tenofovir disoproxil fumarate (TDF) than entecavir (ETV), but this finding remains controversial. We aimed to identify any differences in HCC incidence, or other patient outcomes, between patients receiving TDF or ...

Cited by: 4 Author: George V. Papatheodoridis, George N. D...

Publish Year: 2020

### Incidence and predictors of hepatocellular carcinoma in ...

<https://www.sciencedirect.com/science/article/pii/S0168827814006345>

Feb 01, 2015 · Cumulative incidence of hepatocellular carcinoma (HCC) in 1666 chronic hepatitis B patients treated with entecavir (ETV) and/or tenofovir (TDF). CI, confidence interval. The associations of patients' baseline characteristics with HCC development, estimated by univariable Cox proportional hazards regression models, are presented in Table 2.

Cited by: 129 Author: George V. Papatheodoridis, George N. D...

Publish Year: 2015

### Long-term effect of lamivudine treatment on the incidence ...

<https://pubmed.ncbi.nlm.nih.gov/22231575>

Long-term effect of lamivudine treatment on the incidence of hepatocellular carcinoma in patients with hepatitis B virus infection J Gastroenterol . 2012 May;47(5):577-85. doi: 10.1007/s00535-011-0522-7.

Cited by: 70 Author: Mika Kurokawa, Naoki Hiramatsu, Tsugik...

Publish Year: 2012